Skip Navigation



NDT Advance Access published online on February 9, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh693
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/4/775    most recent
gfh693v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Al-Baaj, F.
Right arrow Articles by Hutchison, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Baaj, F.
Right arrow Articles by Hutchison, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received August 5, 2004
Accepted December 22, 2004

Original Articles

Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study

Fouad Al-Baaj 1, Mary Speake 1, and Alastair J. Hutchison 1*

1 Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, UK

* To whom correspondence should be addressed.
Alastair J. Hutchison, E-mail: alastair.hutchison{at}cmmc.nhs.uk



  Abstract

Background. Hyperphosphataemia in dialysis patients is associated with significant morbidity. We assessed the ability of lanthanum carbonate to control phosphate levels in patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) in a short-term, placebo-controlled study.

Methods. This was a double-blind, placebo-controlled, parallel-group study consisting of three phases: a 2 week washout period; a 4 week, open-label, dose-titration phase; and a 4 week, double-blind, placebo-controlled phase. After washout, patients (n = 59) received lanthanum (375 mg/day), titrated up to a maintenance dose (maximum: 2250 mg) that achieved control of serum phosphate levels between 1.3 and 1.8 mmol/l (4.03-5.58 mg/dl). After titration, patients were randomized to receive their maintenance dose of lanthanum (n = 17) or placebo (n = 19) for 4 weeks. Control of serum phosphate was the primary efficacy assessment. Levels of calcium, parathyroid hormone, calcium x phosphate product and lanthanum as well as adverse events were evaluated.

Results. By the end of titration, 70% of patients had serum phosphate levels ≤1.8 mmol/l. Lanthanum carbonate continued to control serum phosphate levels in the double-blind phase. At the end of the study, 64.7% of lanthanum carbonate-treated patients were controlled compared with 21.4% in the placebo group. Results in patients receiving CAPD were similar to those seen in the group as a whole. Mean parathyroid hormone levels (P = 0.41) and calcium x phosphate product (P<0.001) were both higher in the placebo than the lanthanum carbonate group.

Conclusions. Lanthanum carbonate is an effective phosphate binder able to control serum phosphate and calcium x phosphate product.

Keywords: dialysis; end-stage renal disease; hyperphosphataemia; lanthanum carbonate; phosphate; phosphorus.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
G. Jean, C. Chazot, and B. Charra
Hyperphosphataemia and related mortality
Nephrol. Dial. Transplant., February 1, 2006; 21(2): 273 - 280.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. S Joy, A. Kshirsagar, C. Candiani, T. Brooks, and J. Q Hudson
Lanthanum Carbonate
Ann. Pharmacother., February 1, 2006; 40(2): 234 - 240.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.